FindMyKOL

Carl Landgren, MD

Enriched profile

Hematology / Oncology

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 Miami, FL · Southeast · United StatesSpecialtyHematology / OncologyFocusMultiple Myeloma+1
Active KOLFindMyKOL type: NationalLatest publicationNone indexedOnline presenceNone verifiedPayments2021–2025NIH funding2024–2026Why? →

Carl Landgren is a Multiple Myeloma physician. ClinicalTrials.gov lists 9 registered studies with this person as an investigator.

Data verified 27 Oct 2026

Overview

Updated 27 Oct 2026

Carl Landgren, MD, is profiled from the public federal record. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 25 companies, 1 NIH-funded awards (2024–2026).

  • Top research focus: Multiple Myeloma
  • 9 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 25 companies

Generated from the cited public record · current as of 27 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Multiple Myeloma9 trialsMonoclonal Gammopathy of Undetermined Significance3 trialsSmoldering Multiple Myeloma3 trialsParaproteinemias3 trialsRecurrence1 trial

Research focus

OpenAlex concept fingerprint
Multiple MyelomaSmoldering Multiple Myeloma

Drugs & molecules

across trials, industry payments and publications
Kyprolisgeneric · CarfilzomibClinical trials—Industry payments33Publications—Darzalexgeneric · DaratumumabClinical trials—Industry payments25Publications—Sarclisageneric · IsatuximabClinical trials—Industry payments21Publications—Tecvayligeneric · TeclistamabClinical trials—Industry payments13Publications—Carvyktigeneric · Ciltacabtagene autoleucelClinical trials—Industry payments10Publications—Elrexfiogeneric · ElranatamabClinical trials—Industry payments10Publications—Talveygeneric · TalquetamabClinical trials—Industry payments9Publications—Xpoviogeneric · SelinexorClinical trials—Industry payments7Publications—Dupixentgeneric · DupilumabClinical trials—Industry payments2Publications—Fyarrogeneric · SirolimusClinical trials—Industry payments2Publications—Imbruvicageneric · IbrutinibClinical trials—Industry payments2Publications—Revlimidgeneric · LenalidomideClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
Amgen Inc.Clinical trials—Industry payments33Pfizer Inc.Clinical trials—Industry payments30Genzyme CorporationClinical trials—Industry payments24GlaxoSmithKline, LLC.Clinical trials—Industry payments19Adaptive Biotechnologies CorporationClinical trials—Industry payments17Janssen Biotech, Inc.Clinical trials—Industry payments17Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments17Karyopharm Therapeutics Inc.Clinical trials—Industry payments7Abbvie Inc.Clinical trials—Industry payments6Celgene CorporationClinical trials—Industry payments6E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments5Janssen Research & Development, LLCClinical trials—Industry payments5Janssen Scientific Affairs, LLCClinical trials—Industry payments4University of MiamiClinical trials4Industry payments—Janssen Global Services, LLCClinical trials—Industry payments3National Cancer Institute (NCI)Clinical trials3Industry payments—Aadi Bioscience, Inc.Clinical trials—Industry payments2BeiGene USA, Inc.Clinical trials—Industry payments1BeiGene, Ltd.Clinical trials—Industry payments1Benjamin T Diamond, MDClinical trials1Industry payments—Carl Ola Landgren, MD, PhDClinical trials1Industry payments—Dr.Reddy's Laboratories,Inc.Clinical trials—Industry payments1Merck Sharp & Dohme LLCClinical trials—Industry payments1ModernaTX, Inc.Clinical trials—Industry payments1Sanofi-Aventis U.S. LLCClinical trials—Industry payments1Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments1Tempus AI, IncClinical trials—Industry payments1The Binding Site Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
0h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
9clinical trials

Investigator role on registered studies.

View trials ↓
25companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2024–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Oct 2026

Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:

All 9 trial records: search, sort and filter.Explore →

Industry payments

Updated 27 Oct 2026

25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 58 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2020)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Dermatology

    44.6%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor44.6%
    Acyclovir100%
    Part D≥22 patients

  • Blood & clotting

    14.4%
    Factor Xa inhibitor14.4%
    Xarelto100%
    Part D<11 patients

  • Sensory organs

    12.9%
    Corticosteroid12.9%
    Dexamethasone100%
    Part D<11 patients
All 6 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Oct 2026

1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:

All 19 award records: search, sort and filter.Explore →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Online presence

Updated 27 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    doctors.umiamihealth.org/provider/carl%2Blandgren/1683696

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctors.umiamihealth.org ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.